20
Participants
Start Date
March 9, 2023
Primary Completion Date
March 31, 2026
Study Completion Date
July 31, 2026
Pre-filled syringe, mepolizumab 100 mg/month
Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
Auto-injector pen, mepolizumab 100 mg/month
Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
Service de Pneumologie CHU Dijon, Dijon
Service de Pneumologie CHU Besançon, Besançon
Service de Pneumologie CHU Toulouse, Toulouse
Service des Maladies Respiratoires CHU Reims, Reims
Service de Pneumologie et ImmunoAllergologie CHU Lille, Lille
Departement of Pulmonology, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon
Service de Pneumologie A APHP Bichat, Paris
Service des Maladies Respiratoires CHU Montpellier, Montpellier
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Hospices Civils de Lyon
OTHER